Anti-PI3 Kinase p110 beta Rabbit Monoclonal Antibody for WB and ELISA - P42338

Core Product Specifications and Parameters

Biological Background: PI3 Kinase p110 beta Function and Localization

• PI3 Kinase p110 beta (PIK3CB, P110BETA) is the 110 kDa catalytic subunit beta isoform of class I phosphoinositide 3-kinase (PI3K), encoded by the PIK3CB gene, and also exhibits serine/threonine protein kinase activity with autophosphorylation (PubMed:12502714). Related references: PMID:12502714

• Its primary lipid kinase function is to phosphorylate phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits PH domain-containing proteins like AKT1 and PDPK1 to the plasma membrane, triggering signaling cascades that regulate cell growth, survival, proliferation, motility, and morphology (PubMed:15135396). Related references: PMID:15135396

• Mediates AKT1 activation downstream of G protein-coupled receptors (GPCRs) in response to ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid, and can also transduce signals from receptor tyrosine kinases.

• Plays an essential role in platelet biology by supporting stable platelet adhesion and aggregation induced by thrombin and thromboxane A2, acting through GPCRs, integrin αIIb/β3, and ITAM-bearing receptors like GP6.

• Contributes to the early stages of autophagy by modulating phosphatidylinositol 3-phosphate levels and activating the class III PI3K (PIK3C3), with potential scaffold functions independent of its lipid kinase activity.

• Overexpression or dysregulation is implicated in oncogenic signaling; required for the growth of ERBB2- and RAS-driven tumors, and mediates transformation in PTEN-deficient cells where its lipid kinase activity is essential.

• Subcellular localization includes both cytoplasm and nucleus; the protein is ubiquitously expressed across tissues.

• Keywords highlight its roles in ATP-binding, endocytosis, lipid metabolism, and nucleotide-binding, and it is identified as a phosphoprotein via proteomics.

Experimental Guidance and Technical Tips

• Given the immunogen is an N-terminal peptide (aa 1-100), ensure that detection of full-length p110 beta is not hindered by N-terminal processing or modifications; Western blot optimization may be required.
• For Western blot, the expected band is ~123 kDa; use an appropriate gel percentage (e.g., 6–8% SDS-PAGE) and ensure complete transfer. Include a loading control of similar molecular weight.
• For ELISA, this monoclonal antibody can serve as capture or detection reagent. Pair with another antibody recognizing a non-overlapping epitope for sandwich ELISA development.
• Validate reactivity in relevant human cell lines or tissues (e.g., HeLa, Jurkat, or platelet lysates) as positive controls; consider using PI3K pathway modulators to confirm specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a one-stop sourcing platform for IVD raw materials, offering high-quality antibodies such as this anti-PI3 Kinase p110 beta clone, along with validated antibody pairs, bulk ancillary reagents, and custom solutions for rare targets. With deep expertise in cell signaling and oncology targets, CamelBio streamlines procurement from discovery to clinical applications, supporting diagnostic manufacturers and research laboratories worldwide.